NOV-DEC 2013

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link:

Contents of this Issue


Page 72 of 78

NEWS & EVENTS For the pivotal studies, the primary endpoint was complete cure at Week 52, which required that the target nail show no clinical involvement and no evidence of fungus present by both KOH testing and a negative fungal culture. In Study 1, 17.8% of subjects treated with Jublia were completely cured, compared to only 3.3% of subjects treated with vehicle. In Study 2, 15.2% of subjects treated with Jublia were completely cured, compared to only 5.5% of subjects treated with vehicle. Adverse events that were reported were generally mild and transient and were similar between subjects treated with Jublia and vehicle. The most commonly reported adverse events in treated patients were application site dermatitis and application site vesicles. and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquidinjectable product. Upon closing, Allergan will pay Medytox an upfront payment of U.S. $65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea. Pursuant to the agreement, Allergan has also agreed to make additional contingent payments, including up to an aggregate of U.S. $116.5 million upon achieving certain development milestones, up to an aggregate of U.S. $180.5 million upon achieving certain commercialization milestones, and royalties on product sales. The closing of the transaction is contingent on obtaining certain government approvals. ALLERGAN GAINS EXCLUSIVE RIGHTS TO KOREAN NEUROTOXIN CONSUMERS REPORT A 92% SATISFACTION RATE WITH SOFT TISSUE FILLER TREATMENTS Allergan has entered into an exclusive licensing agreement with Korean pharmaceutical company Medytox to develop A survey of 6,300 consumers found that patients who have received dermal filler injections are satisfied with their treatments Whatever you need, we've got you covered With our 3 creamy mineral foundations each with soothing zinc oxide, SPF 20, superior coverage and a natural looking fnish 1-916-939-9888 1-800-476-0226 toll free w w w. i l l u m i n a re c o s m e t i c s . c o m 68 NOVEMBER/DECEMBER 2013 | MedEsthetics 92% of the time. (Five percent of the total respondents had been treated with dermal fillers.) The American Society for Dermatologic Surgery's Consumer Survey on Cosmetic Dermatologic Procedures asked participants to share their opinions on cosmetic treatments in general and rate 10 specific procedures ranging from botulinum toxin injections to laser treatments and body sculpting. Botulinum toxin and dermal filler treatments were the highest-rated procedures with soft tissue fillers receiving the highest "extremely satisfied" rating (45%). Another 47% said they were "moderately satisfied" with the treatments. More than half of survey respondents (53%) said they are considering soft-tissue fillers in the future, but had not yet undergone the procedure. When asked why they have not yet had a treatment, respondents listed cost (78%), concerns over not getting the desired results (32%) and uncertainty about which practitioner to see (23%) as the most common deterrents. MODERNIZING MEDICINE RECEIVES $14 MILLION IN EQUITY FUNDING Modernizing Medicine (, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific electronic medical record (EMR) system, has received $14 million from Summit Partners, a global growth equity investor. The company provides specialty-specific EMR systems for the dermatology, ophthalmology, optometry, orthopedics, and plastic and cosmetic surgery markets. The EMA system's cloud-based technology is available as a native iPad application or from any web-enabled Mac or PC. This year, Software Advice named EMA the No. 1 tablet EHR. "Our goal is to transform how healthcare information is created, consumed and utilized to increase efficiency and improve patient outcomes," said Daniel Cane, president and CEO of Modernizing Medicine. "With Summit's support, we intend to increase the number of our technological staff to help further our growth in current

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - NOV-DEC 2013